Group 1 - The core viewpoint of the news is that Ruimait Medical Technology Co., Ltd. has seen a stock price increase of 5.09%, reaching 89.20 yuan per share, with a total market capitalization of 7.992 billion yuan [1] - Ruimait specializes in the research, production, and sales of medical devices and consumables in the respiratory health sector, primarily targeting patients with obstructive sleep apnea-hypopnea syndrome (OSA) and chronic obstructive pulmonary disease (COPD) [1] - The company's main business revenue composition includes 64.19% from home respiratory therapy products, 32.67% from consumables, 3.05% from medical products, and 0.10% from other sources [1] Group 2 - According to data, Nord Fund's Nord Small and Mid-Cap Mixed Fund holds 18,000 shares of Ruimait, accounting for 5.02% of the fund's net value, making it the fifth-largest holding [2] - The Nord Small and Mid-Cap Mixed Fund has achieved a year-to-date return of 35.43%, ranking 1958 out of 8154 in its category [2] - The fund manager, Zhu Mingrui, has been in position for 3 years and 114 days, with the best fund return during his tenure being 25.82% [3]

Group 1 - The core viewpoint of the news is that Ruimait's stock price has experienced fluctuations, with a recent decline of 2.06% and a year-to-date increase of 36.38% [1][2] - As of October 23, Ruimait's stock price is reported at 85.38 CNY per share, with a market capitalization of 7.65 billion CNY [1] - The company has seen a net outflow of 485,500 CNY in principal funds, with large orders accounting for 18.86% of purchases and 21.33% of sales [1] Group 2 - Ruimait's main business involves the research, production, and sales of medical devices and consumables in the respiratory health field, primarily targeting patients with obstructive sleep apnea syndrome (OSA) and chronic obstructive pulmonary disease (COPD) [2] - The revenue composition of Ruimait includes 64.19% from home respiratory therapy products, 32.67% from consumables, 3.05% from medical products, and 0.10% from other sources [2] - As of June 30, the number of shareholders decreased by 24.87% to 6,850, while the average circulating shares per person increased by 33.11% to 8,251 shares [3] Group 3 - For the first half of 2025, Ruimait achieved operating revenue of 544 million CNY, representing a year-on-year growth of 42.30%, and a net profit attributable to shareholders of 131 million CNY, also up by 42.19% [3] - Since its A-share listing, Ruimait has distributed a total of 228 million CNY in dividends [4] - As of June 30, 2025, Hong Kong Central Clearing Limited has exited the list of the top ten circulating shareholders [4]

10月16日，瑞迈特涨5.28%，截至发稿，报87.33元/股，成交9744.09万元，换手率2.03%，总市值78.25 亿元。 截至发稿，方纬累计任职时间11年59天，现任基金资产总规模21.27亿元，任职期间最佳基金回报 260.51%， 任职期间最差基金回报-17.22%。 资料显示，北京瑞迈特医疗科技股份有限公司位于北京市丰台区丽泽路16号院4号楼北京汇亚大厦17层 10号，成立日期2001年7月27日，上市日期2022年11月1日，公司主营业务涉及研发、生产、销售呼吸健 康领域医疗设备与耗材产品及相关服务,为以阻塞型睡眠呼吸暂停低通气综合征(OSA)为主的睡眠呼吸暂 停低通气综合征(SAHS)患者以及以慢性阻塞性肺疾病(COPD)为主的呼吸功能不全(Respiratory Insufficiency)患者提供全周期(从诊断、治疗到慢病管理)、多场景(从医疗机构到家庭)的治疗服务整体解 决方案。主营业务收入构成为：家用呼吸诊疗产品64.19%，耗材32.67%，医用产品3.05%，其他 0.10%。 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股 ...

Core Viewpoint - On October 10, 2023, Ruimait experienced a 2.91% increase in stock price with a trading volume of 123 million yuan, indicating positive market sentiment towards the company [1]. Financial Performance - For the first half of 2025, Ruimait achieved a revenue of 544 million yuan, representing a year-on-year growth of 42.30%. The net profit attributable to shareholders was 131 million yuan, also reflecting a growth of 42.19% [2]. - Cumulative cash dividends distributed by Ruimait since its A-share listing amount to 228 million yuan [3]. Shareholder and Market Activity - As of June 30, 2025, the number of shareholders in Ruimait decreased by 24.87% to 6,850, while the average circulating shares per person increased by 33.11% to 8,251 shares [2]. - On October 10, 2023, Ruimait's financing buy-in amounted to 12.20 million yuan, with a net buy of 3.00 million yuan, indicating strong investor interest [1]. - The total balance of margin trading for Ruimait reached 109 million yuan, accounting for 2.25% of its market capitalization, which is above the 50th percentile level over the past year [1]. Business Overview - Ruimait, established on July 27, 2001, specializes in the research, production, and sales of medical devices and consumables in the respiratory health sector, primarily targeting patients with obstructive sleep apnea syndrome (OSA) and chronic obstructive pulmonary disease (COPD) [2]. - The revenue composition of Ruimait includes 64.19% from home respiratory therapy products, 32.67% from consumables, 3.05% from medical products, and 0.10% from other sources [2]. Institutional Holdings - As of June 30, 2025, Hong Kong Central Clearing Limited has exited the list of the top ten circulating shareholders of Ruimait [3].

Core Viewpoint - The stock price of Ruimait has shown a significant increase of 35.98% year-to-date, despite recent declines in the short term, indicating volatility in the market [2]. Company Overview - Ruimait Medical Technology Co., Ltd. specializes in the research, production, and sales of medical devices and consumables in the respiratory health sector, primarily targeting patients with obstructive sleep apnea syndrome (OSA) and chronic obstructive pulmonary disease (COPD) [2]. - The company was established on July 27, 2001, and went public on November 1, 2022 [2]. - The revenue composition includes 64.19% from home respiratory therapy products, 32.67% from consumables, 3.05% from medical products, and 0.10% from other sources [2]. Financial Performance - For the first half of 2025, Ruimait reported a revenue of 544 million yuan, representing a year-on-year growth of 42.30%, and a net profit attributable to shareholders of 131 million yuan, also reflecting a growth of 42.19% [3]. - As of June 30, 2025, the number of shareholders decreased by 24.87% to 6,850, while the average circulating shares per person increased by 33.11% to 8,251 shares [3]. Market Activity - On September 24, Ruimait's stock price rose by 2.04% to 85.13 yuan per share, with a trading volume of 42.52 million yuan and a turnover rate of 0.89%, resulting in a total market capitalization of 7.628 billion yuan [1]. - The net outflow of main funds was 1.355 million yuan, with large orders accounting for 10.85% of purchases and 14.03% of sales [1]. Shareholder and Dividend Information - Since its A-share listing, Ruimait has distributed a total of 228 million yuan in dividends [4]. - As of June 30, 2025, Hong Kong Central Clearing Limited has exited the list of the top ten circulating shareholders [4].

Group 1 - The core viewpoint of the news is that Ruimait has experienced a decline in stock price, with a cumulative drop of 6.36% over four consecutive days, currently trading at 85.52 yuan per share [1] - Ruimait Medical Technology Co., Ltd. specializes in the research, production, and sales of medical devices and consumables in the respiratory health field, primarily serving patients with obstructive sleep apnea syndrome (OSA) and chronic obstructive pulmonary disease (COPD) [1] - The company's main business revenue composition includes 64.19% from home respiratory therapy products, 32.67% from consumables, 3.05% from medical products, and 0.10% from other sources [1] Group 2 - According to data, Nord Fund holds a significant position in Ruimait, with its Nord Small and Mid-Cap Mixed Fund (570006) owning 18,000 shares, accounting for 5.02% of the fund's net value [2] - The fund has incurred a floating loss of approximately 10.46 million yuan during the four-day decline [2] - The Nord Small and Mid-Cap Mixed Fund has achieved a return of 45% year-to-date, ranking 1247 out of 8244 in its category [2]

Investment Rating - The report maintains a "Buy" rating for the company [7] Core Views - The company has shown continuous improvement in revenue quarter-on-quarter, with significant growth in the US and European markets. The inventory destocking cycle in the US has ended, and the European market has begun to enter mainstream medical insurance markets. Domestic market adjustments are showing initial results, leading to dual growth in revenue and profit in Q2 2025 [2][4] - The company’s new noise-reducing cotton ventilator has been launched in the US market, with expectations for increased volume in the second half of the year. The company is deepening its localization strategy overseas, enhancing its global competitiveness [2][3] Financial Performance - In H1 2025, the company achieved operating revenue of 544 million yuan, a year-on-year increase of 42.30%, and a net profit attributable to the parent company of 131 million yuan, also up 42.19%. In Q2 2025, revenue reached 279 million yuan, growing 46.54% year-on-year, with a net profit of 59.41 million yuan, up 39.92% [1][4] - The company’s gross margin in Q2 2025 was 54.64%, an increase of 2.98 percentage points year-on-year. The sales expense ratio decreased by 1.82 percentage points to 12.75%, while the management expense ratio fell by 3.20 percentage points to 6.65% [2] Business Segments - The company’s main business lines showed strong growth in H1 2025: - Home respiratory therapy products generated revenue of 349 million yuan, up 51.49% year-on-year, with a gross margin of 45.02% - Consumables generated revenue of 178 million yuan, up 30.26%, with a gross margin of 65.83% - Medical products generated revenue of 16.56 million yuan, up 12.96%, with a gross margin of 55.77% [3] - Domestic revenue reached 191 million yuan in H1 2025, a year-on-year increase of 16.87%, while overseas revenue was 353 million yuan, up 61.33% [4] Market Outlook - The company is expected to see revenue growth of 27.7%, 22.6%, and 21.2% for the years 2025, 2026, and 2027, respectively, with net profits projected to grow by 76.0%, 31.5%, and 23.0% in the same years [4]

Company Overview - Beijing Ruimait Medical Technology Co., Ltd. was established on July 27, 2001, and went public on November 1, 2022. The company specializes in the research, production, and sales of medical devices and consumables in the respiratory health field, primarily targeting patients with Obstructive Sleep Apnea Syndrome (OSA) and Chronic Obstructive Pulmonary Disease (COPD) [2] Business Performance - For the first half of 2025, the company achieved operating revenue of 544 million yuan, representing a year-on-year growth of 42.30%. The net profit attributable to the parent company was 131 million yuan, also reflecting a year-on-year increase of 42.19% [2] - The revenue composition includes 64.19% from home respiratory therapy products, 32.67% from consumables, 3.05% from medical products, and 0.10% from other sources [2] Stock Performance - On September 5, the stock price of Ruimait increased by 2.09%, reaching 88.75 yuan per share, with a trading volume of 64.83 million yuan and a turnover rate of 1.31%. The total market capitalization is 7.952 billion yuan [1] - Year-to-date, the stock price has risen by 41.77%, while it has decreased by 2.24% over the last five trading days and by 3.75% over the last twenty days [1] Shareholder Information - As of June 30, 2025, the number of shareholders was 6,850, a decrease of 24.87% from the previous period. The average number of circulating shares per person increased by 33.11% to 8,251 shares [2] - Since its A-share listing, the company has distributed a total of 228 million yuan in dividends [3] Institutional Holdings - As of June 30, 2025, Hong Kong Central Clearing Limited has exited the list of the top ten circulating shareholders [3]

Investment Rating - The investment rating for the company is "Buy" [1] Core Views - The company has shown a recovery in revenue growth quarter by quarter, with a significant increase in the proportion of consumables in its business [2] - The company is increasing its R&D investment and optimizing its supply chain, which is expected to enhance profitability [2] - Revenue forecasts for 2025-2027 indicate a positive growth trajectory, with expected revenues of 10.58 billion, 13.14 billion, and 16.21 billion respectively, and corresponding net profits of 2.06 billion, 2.69 billion, and 3.43 billion [2] Summary by Relevant Sections Financial Performance - In 2024, the company achieved total revenue of 843 million (down 24.85% YoY) and a net profit of 155 million (down 47.74% YoY) [3] - The revenue for Q4 2024 was 241 million (up 36.29% YoY), with a net profit of 30 million (up 12.65% YoY) [3] - The company’s gross margin improved to 48.3% in 2024, with a projected gross margin of 49.3% in 2025 [3] Revenue Breakdown - The company’s consumables revenue reached 284 million in 2024, representing a 46.22% increase YoY, and accounted for 33.72% of total revenue [2] - The revenue from home respiratory therapy products was 527 million (down 38.15% YoY), primarily due to inventory destocking in overseas markets [2] Profitability Metrics - The sales expense ratio increased to 13.36% (up 4.06 percentage points YoY), while the management expense ratio rose to 7.29% (up 3.70 percentage points YoY) [2] - The net profit margin for 2024 was 18.80% (down 7.91 percentage points YoY) [2] Future Projections - Expected revenue growth rates for 2025, 2026, and 2027 are 25.4%, 24.2%, and 23.4% respectively [2] - The projected net profit growth rates for the same period are 32.4%, 30.6%, and 27.7% respectively [2]